Date

01/29/2010

Text to display

N/A

Subject

AHRQ Draft TA review period extended

Content

Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment Program review period for the draft technology assessment entitled "Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia" has been extended to February 12, 2010 due to a delayed (January 28) posting of the associated appendices. If you are interested in reviewing this document, please visit: http://www.ahrq.gov/clinic/ta/tareview.htm. The document will be available for review from 9:00 AM on January 27, 2010 to 5:00 PM on February 12, 2010. If you have any questions, please contact ahrqtap@ahrq.hhs.gov.